Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM. Kuritzkes DR, et al. Among authors: kessler h. J Infect Dis. 2000 Feb;181(2):491-7. doi: 10.1086/315244. J Infect Dis. 2000. PMID: 10669331 Clinical Trial.
Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.
Hulgan T, Donahue JP, Smeaton L, Pu M, Wang H, Lederman MM, Smith K, Valdez H, Pilcher C, Haas DW; AIDS Clinical Trials Group Study A5138 Team. Hulgan T, et al. Eur J Clin Pharmacol. 2009 Nov;65(11):1081-8. doi: 10.1007/s00228-009-0725-5. Eur J Clin Pharmacol. 2009. PMID: 19779705 Free PMC article. Clinical Trial.
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, Kessler H. Lederman MM, et al. Among authors: kessler h. J Infect Dis. 1998 Jul;178(1):70-9. doi: 10.1086/515591. J Infect Dis. 1998. PMID: 9652425 Clinical Trial.
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.
Valdez H, Smith KY, Landay A, Connick E, Kuritzkes DR, Kessler H, Fox L, Spritzler J, Roe J, Lederman MB, Lederman HM, Evans TG, Heath-Chiozzi M, Lederman MM. Valdez H, et al. Among authors: kessler h. AIDS. 2000 Jan 7;14(1):11-21. doi: 10.1097/00002030-200001070-00002. AIDS. 2000. PMID: 10714563 Clinical Trial.
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.
Landay AL, Spritzler J, Kessler H, Mildvan D, Pu M, Fox L, O'Neil D, Schock B, Kuritzkes D, Lederman MM; AIDS Clinical Trials Group 5014 Team. Landay AL, et al. Among authors: kessler h. J Infect Dis. 2003 Nov 15;188(10):1444-54. doi: 10.1086/379041. Epub 2003 Nov 13. J Infect Dis. 2003. PMID: 14624369 Clinical Trial.
1,223 results